

Panel Discussion : NIH AREA R15 grant

Friday February 12th
2021 - 12:00 pm (Central Time)



Dr. Hector Biliran is a Professor, Department of Biology, Xavier University of Louisiana, New Orleans, LA. He received his Ph.D. in the Molecular and Cellular Pathobiology program of Wayne State University, Department of Pathology, Detroit, MI in Dec., 2007. Following his graduate work, he focused on establishing his cancer research expertise on the molecular mechanisms and regulators of cancer cell survival and apoptosis. He did his post-doctoral research work in the laboratory of Dr. Erkki Ruoslahti at the NCI-designated Cancer Center, Sanford-Burnham Medical Research Institute, examining the novel Bcl2-inhibitor of transcription (Bit1) caspase-independent apoptotic pathway. Hector Biliran is an associate member of the Associate Member, American Association for Cancer Research (AACR) and Louisiana Cancer Research Consortium (LCRC). R15 CA158677-02, National Cancer Institute (NCI) - The major goal of this study is to elucidate the role of the Bit1 cell death machinery in the initiation and progression of NSCLC and as a molecular therapeutic target in lung cancer therapy. R15 CA158677-01A1, National Cancer Institute (NCI) - The goal of this project is to examine the role of Bit1 in the apoptosis resistance and survival of NSCLC cells and its potential use as a therapeutic target in alleviating NSCLC chemoresistance.

